Beatrice Nolan

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry

Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B